Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is only speculation on your behalf
Do you have the stats on how quickly they dump their shares, as you have alluded?
Ofcourse they are hedge funds. You expected them to be a charity?
Might come as a surprise but everyone is here to make money
But since you hint they could dump their shared quickly, you tell me what their average is in holding new shares.
Ugh another meaningless investor for some. Probably they already dumped their shares due to pump and dump and the tiny trials with no scientific meaning.
Personally, I am happy to see further conformation from tutes'
You sound surprised Wait. I am not, I always thought this was the plan.
Believe it was even stated in a webinar.
As for the "hard to reach tumor", that is lingo for their current R&D project on the minuscule device that can go anywhere in the body.
Upwards and onwards
Upward and Onwards: OncoSec Moves to The NASDAQ Capital Market
On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.
As an immediate benefit, we’ve already seen that our listing on the NASDAQ has allowed us to approach new investors, who have restrictions or policies that prevent them from investing in OTC-listed companies. More investors are now able to analyze and invest in our company, and take part in OncoSec’s story as a leader in the immuno-oncology landscape. OncoSec will also continue to leverage the “NASDAQ” brand to support international growth and gain investor access.
Looking to the future, we hope to validate our technology beyond the scientific community and reach established, dedicated investors, who share our vision for the future of cancer care. We are now in a better position to continue to advance our intratumoral immunotherapy technologies with the goal of one day benefiting cancer patients everywhere.
I recently had the opportunity to speak with The San Diego Business Journal on our journey, the impact of becoming a NASDAQ-listed company, and what the future holds for OncoSec.
Biotech Prepares Financially, Clinically
The San Diego Business Journal
June 8, 2015
Brittany Meiling
OncoSec Medical Inc., a public biotech company that’s operated largely under the radar in San Diego, has uplisted to the NASDAQ in a move to attract investors with more weight.
The company was previously listed on the over-the-counter market, an exchange that hasn’t earned the same credibility as major players on Wall Street, such as the New York Stock Exchange and NASDAQ. OTC stocks, often called penny stocks or pink sheets have a reputation for being risky. And OncoSec wants to up its game.
“While we’ve experienced a lot of growth over the last year, we haven’t been able to get recognition on the marketplace because trading on OTC limits your investors,” said OncoSec’s co-founder and CEO Punit Dhillon. “Being on the NASDAQ heightens our credibility and broadens our base of institutional investors.”
The company held a 1-for-20 reverse stock split in May to prepare for the uplisting, which increased OncoSec’s share price to about $6 per share from pennies and dimes. Note that the reverse stock split doesn’t actually up the company’s value, but reduces the number of shares outstanding.
Growth Despite Challenges
For a biotech, OncoSec has grown quite rapidly over the last year. Its employee base more than doubled from 24 in January 2014 to 55 employees today.
Since its inception in 2011, Dhillon, 34, has grown the company from a $20 million market cap value to nearly $74 million, and raised $74 million in working capital for the company to date. Today, OncoSec has a cash runway of almost two years, and multiple clinical programs to keep it busy.
Still, OncoSec has found it difficult to climb the charts. The company’s stock has declined about 35 percent over the year, and in early May the company recorded a new 52-week low, with its stock trading at $0.26 per share.
Dhillon said the lack of traction was primarily due to the market in which the company was trading. “True valuation is never reflected until we get an exit opportunity,” Dhillon said. “Everything in-between is just noise.”
Fingers Crossed
While OncoSec has struggled to receive recognition in the marketplace, new developments in caner research indicate the company might be on the right track for a lucrative breakthrough therapy.
OncoSec’s main game is to increase the effectiveness of immunotherapy, which is a way to treat illness by stimulating the body’s own immune system. Findings presented at the American Association of Cancer Research conference in April recognized immunotherapy’s effectiveness in treating cancer, and projected that it would be the standard of care in the near future. Science magazine also announced in the same month that immune checkpoint therapy joined the ranks of surgery, radiation and chemotherapy as a pillar of cancer treatment. It’s possible that OncoSec’s proprietary technology, called ImmunoPulse, could increase the effectiveness of a popular immunotherapy treatment called anti-PD-1.
The effectiveness of this type of immunotherapy depends on the presence of T-cells, the soldier cells of the immune system. But not everyone has the right kind of T-cells in their body. In fact, anywhere from 60 percent to 80 percent of patients with cancer don’t have the right kind of T-cells to respond to anti-PD-1 therapy.
“No matter how successful the immunotherapy approach may be, if the vast majority of patients aren’t responding then its likely that health insurance companies will not want to pay for the drug, Dhillon said.
Now here’s the cool part. ImmunoPulse uses electricity to zap cancer cells causing tiny pores to briefly appear in the cell membranes. This “electroporation” allows drugs or compounds to be delivered directly to a tumor site, which then activates a systemic response throughout the entire body. If the compound delivered through this system is a protein called interleukin 12, it will kick up the presence of T-cells at all tumor sites, Dhillon said.
With the soldier cells in place, the anti-PD-1 therapy could be significantly more effective.
Vote of Confidence
This is why the University of California, San Francisco has entered into a collaboration with OncoSec to test how the company’s technology combines interleukin 12 with anti-PD-1 therapies. OncoSec has even attracted the attention of pharma giant Merck & Co., which provided its anti-PD-1 drug Keytruda at no cost to the San Diego biotech for its clinical trials.
If the Phase 2 trial testing the combination in melanoma goes well, OncoSec could soon be primed for a successful exit.
Bristol Meyers Squibb Co., Merck, Roche Holding AG and other drug makers are racing for a share of the burgeoning cancer immunotherapy market which some analysts predict could reach $20 billion to $30 billion in annual sales in the next decade.
As far as OncoSec’s technology goes, Dhillon said he feels hopeful.
“We want to give the immune system of bit of a nudge,” Dhillon said. “Like plugging in a USB stick and retraining the defense system. We want to treat any type of tumor, even the hard to reach ones.”
Oh no an unreal, insignificant trial with dummy people!
Ceo must be fake and the chief med a nice guy.
OncoSec Medical Set to Join Russell Microcap Index
Oh well, I'm sure that this will be discarded by some as completely meaningless.
OncoSec Medical Set to Join Russell Microcap Index
DOWNLOAD AS PDF
JUNE 15, 2015
SAN DIEGO, June 15, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it is set to join the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26, according to a preliminary list of additions posted on June 12.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
"We are pleased to be added to the Russell Microcap Index to raise OncoSec's visibility and public awareness within the investment community," said Punit Dhillon, President and CEO of OncoSec. "As we continue to execute on our growth strategy, we believe our inclusion in this index will serve as a valuable tool to help broaden our shareholder base and further advance our intratumoral immunotherapy products."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 1000 and the Russell indexes reconstitution, please visit the "Recon Central" section on the FTSE Russell website.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 80 countries, covering 98% of the investable market globally and trading on over 25 exchanges worldwide. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Leading asset owners, asset managers, ETF providers and investment banks use FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance. FTSE Russell is also focused on index innovation and client collaboration as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, please visit www.ftserussell.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulseTM intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulseTM have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulseTM for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulseTM in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Hold it doc. Did you bother contacting him? I have and this is Punits reply:
I would like to buy more, but I’m hving an issue with my broker compliance because I’m an officer of OncoSec.
So I am expecting more when the issue is settled.
One more reason to uplist asap!
Marlin, thx for sticking around, most informative postings you have
We have been waiting for this one a long time! Although the sitze could have been a bit bigger ;)
Please explain how you know they are small fry as their identity is unknown (to my best knowledge). But hey if you know more about it then please share !
Did you listen to yesterdays call at all??
yes I do
Correction: not persuing at this stage.
Today is the first day of a new phase for Oncosec. A phase were the brutal market manipulation that comes with being OTC will be less significant. Let this be the beginning of an increased institutional base. Sure there will be darker days ahead but the best lay ahead.
Looking forward to seeing the combo trial with detailed protocol recruit its 1st patient. And the size of the trial in itself is not the goal. Keep in mind this is determined with the FDA. It has to be statidtically significant and prove that electroporated IL-12 will greatly enlarge the population that can be treated with Keytruda. Upon this hinges Oncosecs future.
As for dilution, our runway is over a year so it might happen. But a good biotech does it when it doesn't need too, from a position of strength. Lets wait and see what happens institutionally in the next couple of months.
are they running late? supposed to start 10 min ago...
I got in at 3.20 and bought more at 2.80. Anyone of jbems list still holding on to this one?
All they need to proof is that the concept works and that the trial is stat significant.
If proven, many big boys will be interested.
Do you believe in the science behind the company and the objectives they try to achieve?
No proof that the FDA has rejected the trial protocol!
The whole RS is not done to please rretail shareholders. If anything, the last year must have shown Punit what a bunch of crybabies were invested. So he wants to shake them out so big, non-emotional boys can come in. I am happy to hold, realizing that probably nothing new will happen till end of year or early 16 when combo trial results come in'
I do expect the announcment of the 1st patient combo trial very soon as part of the current RS-scenario that is unrolling.
Mld to moderate toxicity, anything to be concerned about?
I bought into TPIV aswell, but still holding on to my AVXL and PTBI's ;)
Keep it going jbem, you seem to have some magic!
Shoo bear
Red-hot PlasmaTech Biopharmaceuticals (PTBI +47.2%) closes a $10M private placement of common stock with an institutional investor at $8 per share (1.25M shares). The investor will also be issued warrants to purchase 625K shares of common stock at $10 per share. Closing date is May 11.
About a month ago, the company closed a private offering of 2.3M shares of common stock at $3. Investors are, no doubt, smiling broadly right now.
source:seeking alpha
There are only 20 mil shares, so far 12 mil changed hands today.
So who got in and who got out??
Between 12/31/14 and 04/22/14, Soros added 916667 shares.
On 04/15/15 alone 2,71 mil shares exchanged hands. So I guess mr Soros did not have a hard time accumulating.
Interested to know what the next resistance points are on the way down.
So far Citrati and 123tom were spot on.
Today I decided to skip the .28 resistance. But would like to know where to put a lower order in.
Crazy biotech world. Cannot understand as to the why of it all.
Source please jbem.
Do you seriously believe this?
Have a look at this article, seems a lot plausibler answer:
The secret trading strategy from the 1930s that hedge funders don’t want you to know about
What is there to say about Merck?
No there is curently no partnership
Yes Merck is providing Keytruda for free in a USCF sponsored combo trial
Yes a partnership hinges on positive combo trial results
New information: combination trial will have a patient size of 40-50 patients and will be statistically significant. Interim data to be expected at the earliest by Q4 and if all parties agree to releasing.
Also, they are working on a device that can go anywhere in the body to electroporate. This can have significant value at a later stage.
In my humble opinion, Oncosec is putting eveything in place to be a big winner. But, all will depent on positive combo trial results!
I feel comfortable holding my shares to await the results. If it gets manipulated down again, I will add.
email to CFO:
Dear Mr. xxxx
Thank you for your inquiry. Fortunately, with careful cash management, we have been able to extend the cash position for a short time while. As stated in our filings, we are focused on raising additional capital.
Thank you for your support as an investor in Arch.
Regards,
Rick
So I have took my profit at .23 and will re-enter after dilution is announced.
Lol, impossible to prove does not equal it does not happen. Thanks.
http://philosophy.hku.hk/think/logic/
Lol
So that still does not mean it is not ongoing behind the scenes.
You cannot prove it is not happening
thanks
You cannot confirm either that buyout talks have not been taking part.
So who knows?
Could you help me out and link it?
27447 is definatly your post doc
dr_lowenstein Member Level Friday, 12/05/14 04:06:40 PM
Re: cameron12x post# 27433
Post # of 28063
I saw that and I remain cautiously optimistic but several matters to keep in mind: 1. This is yet another Investigator Sponsored Trial. While these studies can yield important scientific information, they have less weight with FDA. The agency wants sponsored studies. 2. While Merck is supplying drug for the trail, that appears to be the extent of their involvement, so this is not really a big pharma collaboration in the usual sense of the term. 3. If the trail starts in Q1/15 it will be a considerable period of time until completed and results are known.
"This Phase II clinical trial will be conducted as a multicenter Investigator Sponsored Trial (IST), with UCSF and Dr. Alain Algazi as the sponsor. Merck will supply pembrolizumab, and OncoSec will provide electroporation devices and plasmid IL-12. Enrollment is expected to begin in Q1 2015."
What is the difference between sponsering a trial or providing Keytruda?
Even the queen of England is replacable.
Plain and simple: unable to further discuss.
If the sole thing Merck do or will do is to provide the PD1 for free, then ONCS could have said so, as this is already public knowledge.